BioVie
Open
$1.64
Prev. Close
$1.64
High
$1.65
Low
$1.64
Market Snapshot
$11.91M
-0.7
-34.60
13
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
emptyResult
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Recently from Cashu
BioVie Under Investigation for Potential Fiduciary Duty Breaches Amid Shareholder Concerns
BioVie Faces Scrutiny: Potential Breaches of Fiduciary Duties Under Investigation BioVie Inc., a biopharmaceutical company focused on developing innovative therapies for liver diseases, is currently u…
BioVie Stock Insights: Key Updates and Market Trends
I'm sorry, but it seems that you haven't provided the text you want me to summarize. Please share the content, and I'll assist you in creating a summary as per your requirements.
BioVie’s NE3107 Shows Promise in Alzheimer's Treatment with Phase 2 Trial Results
BioVie Advances Alzheimer’s Treatment with Promising Clinical Trial Results BioVie Inc. is making significant strides in the field of neurodegenerative disease treatment, particularly focusing on Alzh…
BioVie Stock Analysis: Insights and Future Prospects
Certainly! Please provide the text you'd like me to summarize, and I'll create an article based on your requirements.